• Something wrong with this record ?

Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation

M. Kauke-Navarro, OF. Noel, L. Knoedler, S. Knoedler, AC. Panayi, VA. Stoegner, L. Huelsboemer, B. Pomahac

. 2023 ; 291 (-) : 176-186. [pub] 20230708

Language English Country United States

Document type Journal Article, Review

INTRODUCTION: Despite the clinical success in vascularized composite allotransplantation (VCA), systemic immunosuppression remains necessary to prevent allograft rejection. Even with potent immunosuppressive regimens (tacrolimus, mycophenolate mofetil, and steroids), most patients experience several rejection episodes, often within the same year. The risk of systemic side effects must constantly be weighed against the risk of under-immunosuppression and, thus, acute and chronic rejection. In this context, genomic editing has emerged as a potential tool to minimize the need for toxic immunosuppressive regimens and has gained attention in the fields of solid organ transplantation and xenotransplantation. This strategy may also be relevant for the future of VCA. METHODS: We discuss the topic of genetic engineering and review recent developments in this field that justify investigating tools such as clustered regularly interspaced short palindromic repeats/Cas9 in the context of VCA. RESULTS: We propose specific strategies for VCA based on the most recent gene expression data. This includes the well-known strategy of tolerance induction. Specifically, targeting the interaction between antigen-presenting cells and recipient-derived T cells by CD40 knockout may be effective. The novelty for VCA is a discovery that donor-derived T lymphocytes may play a special role in allograft rejection of facial transplants. We suggest targeting these cells prior to transplantation (e.g., by ex vivo perfusion of the transplant) by knocking out genes necessary for the long-term persistence of donor-derived immune cells in the allograft. CONCLUSION: Despite the demonstrated feasibility of VCA in recent years, continued improvements to immunomodulatory strategies using tools like clustered regularly interspaced short palindromic repeats/Cas9 could lead to the development of approaches that mitigate the limitations associated with rejection of this life-giving procedure.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24003183
003      
CZ-PrNML
005      
20240509113208.0
007      
ta
008      
240220e20230708xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jss.2023.04.028 $2 doi
035    __
$a (PubMed)37429217
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kauke-Navarro, Martin $u Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts; Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut
245    10
$a Novel Strategies in Transplantation: Genetic Engineering and Vascularized Composite Allotransplantation / $c M. Kauke-Navarro, OF. Noel, L. Knoedler, S. Knoedler, AC. Panayi, VA. Stoegner, L. Huelsboemer, B. Pomahac
520    9_
$a INTRODUCTION: Despite the clinical success in vascularized composite allotransplantation (VCA), systemic immunosuppression remains necessary to prevent allograft rejection. Even with potent immunosuppressive regimens (tacrolimus, mycophenolate mofetil, and steroids), most patients experience several rejection episodes, often within the same year. The risk of systemic side effects must constantly be weighed against the risk of under-immunosuppression and, thus, acute and chronic rejection. In this context, genomic editing has emerged as a potential tool to minimize the need for toxic immunosuppressive regimens and has gained attention in the fields of solid organ transplantation and xenotransplantation. This strategy may also be relevant for the future of VCA. METHODS: We discuss the topic of genetic engineering and review recent developments in this field that justify investigating tools such as clustered regularly interspaced short palindromic repeats/Cas9 in the context of VCA. RESULTS: We propose specific strategies for VCA based on the most recent gene expression data. This includes the well-known strategy of tolerance induction. Specifically, targeting the interaction between antigen-presenting cells and recipient-derived T cells by CD40 knockout may be effective. The novelty for VCA is a discovery that donor-derived T lymphocytes may play a special role in allograft rejection of facial transplants. We suggest targeting these cells prior to transplantation (e.g., by ex vivo perfusion of the transplant) by knocking out genes necessary for the long-term persistence of donor-derived immune cells in the allograft. CONCLUSION: Despite the demonstrated feasibility of VCA in recent years, continued improvements to immunomodulatory strategies using tools like clustered regularly interspaced short palindromic repeats/Cas9 could lead to the development of approaches that mitigate the limitations associated with rejection of this life-giving procedure.
650    _2
$a lidé $7 D006801
650    _2
$a rejekce štěpu $x prevence a kontrola $7 D006084
650    12
$a vaskularizovaná kompozitní alotransplantace $x metody $7 D063986
650    _2
$a homologní transplantace $7 D014184
650    12
$a transplantace orgánů $7 D016377
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a genetické inženýrství $7 D005818
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Noel, Olivier F $u Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut
700    1_
$a Knoedler, Leonard $u Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
700    1_
$a Knoedler, Samuel $u Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
700    1_
$a Panayi, Adriana C $u Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
700    1_
$a Stoegner, Viola A $u Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut; Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany
700    1_
$a Huelsboemer, Lioba $u Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut; Institute of Musculoskeletal Medicine, University Hospital Muenster, Münster, Germany
700    1_
$a Pomahac, Bohdan $u Division of Plastic and Reconstructive Surgery, Department of Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, Connecticut. Electronic address: bohdan.pomahac@yale.edu
773    0_
$w MED00002957 $t The Journal of surgical research $x 1095-8673 $g Roč. 291 (20230708), s. 176-186
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37429217 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240220 $b ABA008
991    __
$a 20240509113202 $b ABA008
999    __
$a ok $b bmc $g 2088839 $s 1212923
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 291 $c - $d 176-186 $e 20230708 $i 1095-8673 $m The Journal of surgical research $n J Surg Res $x MED00002957
LZP    __
$a Pubmed-20240220

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...